title: The application of impulse oscillation system for the evaluation of treatment effects in patients with COPD.
abstract: There are only a few reports of the use of impulse oscillation system (IOS) for the evaluation of COPD treatment. In this study, we applied IOS and spirometry to evaluate the effectiveness of fluticasone propionate and salmeterol (SFC) combined with tiotropium (TIO) in COPD patients. Following a 4-week run-in period with TIO (18 μg once daily) treatment, COPD patients were randomized to SFC (250/50 μg twice daily; SFC+TIO group, n=25), or TIO alone (TIO group, n=31). Pulmonary functions were recorded by IOS and spirometry before and after the study period. The SFC+TIO group showed significant improvements in inspiratory resistance at 5 Hz and resonant frequency, as well as in FVC and FEV1, after the 12-week treatment (p<0.05). Since there were no significant correlations between improvements in IOS measurements and FVC or FEV1, IOS may provide a physiological point of view that is different from spirometry and seemed to be applicable as an additional assessment tool targeting COPD patients.
authors.affiliation: Division of Respiratory and Infectious Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki 216-8511, Japan. Electronic address: m-mine@marianna-u.ac.jp.
authors.forename: M
authors.initials: M
authors.lastname: Mineshita
authors.affiliation: Respiratory Disease Center, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tuzuki-ku, Yokohama, Japan. Electronic address: shikamay@med.showa-u.ac.jp.
authors.forename: Y
authors.initials: Y
authors.lastname: Shikama
authors.affiliation: Respiratory Disease Center, Showa University Northern Yokohama Hospital, 35-1 Chigasaki-chuo, Tuzuki-ku, Yokohama, Japan. Electronic address: hiroaki@med.showa-u.ac.jp.
authors.forename: H
authors.initials: H
authors.lastname: Nakajima
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomiokahigashi, Kanazawa-ku, Yokohama 236-0051, Japan. Electronic address: nishihira@kanagawa-junko.jp.
authors.forename: R
authors.initials: R
authors.lastname: Nishihira
authors.affiliation: Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, 6-16-1 Tomiokahigashi, Kanazawa-ku, Yokohama 236-0051, Japan. Electronic address: komatsu-s@kanagawa-junko.jp.
authors.forename: S
authors.initials: S
authors.lastname: Komatsu
authors.affiliation: Respiratory Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Sagamihara 228-8555, Japan. Electronic address: mkubota@med.kitasato-u.ac.jp.
authors.forename: M
authors.initials: M
authors.lastname: Kubota
authors.affiliation: Graduate School of Medical Sciences, Kitasato University, 1-15-1 Kitasato, Sagamihara 228-8555, Japan. Electronic address: hiro@kitasato-u.ac.jp.
authors.forename: H
authors.initials: H
authors.lastname: Kobayashi
authors.affiliation: Department of Respiratory Medicine, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227-8501, Japan. Electronic address: fkokubu@med.showa-u.ac.jp.
authors.forename: F
authors.initials: F
authors.lastname: Kokubu
authors.affiliation: Respiratory Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan. Electronic address: shinkai@yokohama-cu.ac.jp.
authors.forename: M
authors.initials: M
authors.lastname: Shinkai
authors.affiliation: Respiratory Disease Center, Yokohama City University Medical Center, 4-57 Urafune-cho, Minami-ku, Yokohama 232-0024, Japan. Electronic address: takeshi@med.yokohama-cu.ac.jp.
authors.forename: T
authors.initials: T
authors.lastname: Kaneko
authors.affiliation: Division of Respiratory and Infectious Diseases, Department of Internal Medicine, St. Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki 216-8511, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Miyazawa
mesh_terms: D000368:Aged; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009991:Oscillometry; D017063:Outcome Assessment, Health Care; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology*; D000068299:Salmeterol Xinafoate; D012602:Scopolamine Derivatives / Q000627:therapeutic use*; D013147:Spirometry; D011795:Surveys and Questionnaires; D000069447:Tiotropium Bromide
chemical_list: D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D000068299:Salmeterol Xinafoate; D000420:Albuterol; D000069447:Tiotropium Bromide
keywords: Bronchodilators; Chronic obstructive pulmonary disease; Impulse oscillometry; Pulmonary function test